Why would a 60‑year‑old man with symptomatic hypogonadism need to target a serum testosterone level of approximately 850 ng/dL?

Why Target Testosterone of 850 ng/dL in a 60-Year-Old Man?

A target testosterone level of 850 ng/dL is not evidence-based and exceeds guideline-recommended targets for testosterone replacement therapy in men with hypogonadism.

Guideline-Recommended Target Range

The American Urological Association explicitly recommends targeting the middle tertile of the normal reference range (450–600 ng/dL) for testosterone replacement therapy, not supraphysiologic levels. 1, 2 This mid-normal target applies across all adult age groups, including men over 60 years. 3, 2

• For injectable testosterone formulations, levels should be measured midway between injections and should target 500–600 ng/dL. 1, 2
• The goal is normalization of testosterone levels combined with symptom improvement, not maximization of hormone concentrations. 2
• Treatment programs should use the minimal dosing necessary to achieve physiologic testosterone levels of 450–600 ng/dL. 2

Why 850 ng/dL Is Inappropriate

Safety Concerns with Supraphysiologic Levels

Targeting 850 ng/dL places the patient in the upper range of normal or potentially supraphysiologic territory, significantly increasing the risk of erythrocytosis and other adverse effects. 1

• Injectable testosterone already carries a 43.8% risk of developing hematocrit >52%, the highest among all formulations. 1
• Peak serum levels 2–5 days after injection often transiently exceed the upper limit of normal even with standard dosing targeting mid-normal ranges. 1
• Elevated hematocrit increases blood viscosity and can exacerbate coronary, cerebrovascular, and peripheral vascular disease—particularly dangerous in a 60-year-old man who likely has age-related cardiovascular risk factors. 1

Lack of Additional Clinical Benefit

There is no evidence that higher testosterone levels within or above the normal range provide greater symptomatic benefit than mid-normal levels. 1, 4

• Testosterone therapy produces only a small improvement in sexual function (standardized mean difference 0.35) even when levels are normalized to mid-range. 1
• Little to no benefit is seen for energy, vitality, physical functioning, depressive symptoms, or cognition regardless of the testosterone level achieved within the therapeutic range. 1
• Quality-of-life improvements are modest and confined primarily to sexual function domains. 1

Appropriate Clinical Approach for a 60-Year-Old Man

Diagnostic Confirmation Required First

Before any discussion of target levels, confirm biochemical hypogonadism with two separate fasting morning (8–10 AM) total testosterone measurements both <300 ng/dL. 1, 3, 2

• Single measurements are insufficient due to diurnal variation and assay variability. 1, 3
• In men with obesity (common at age 60), measure free testosterone by equilibrium dialysis or calculate the free androgen index, as low SHBG may artificially lower total testosterone while free testosterone remains normal. 1, 3
• Measure LH and FSH to distinguish primary from secondary hypogonadism, which has critical treatment implications including fertility preservation options. 1

Symptom Assessment

Testosterone therapy is justified only when diminished libido and/or erectile dysfunction are present as primary symptoms. 1

• Nonspecific complaints such as fatigue, low energy, mood changes, or "brain fog" do not reliably improve with testosterone therapy and should not drive treatment decisions. 1
• Approximately 20–30% of men over 60 have testosterone in the low-normal range, but this does not constitute disease requiring treatment in the absence of specific sexual symptoms. 1

Monitoring Protocol When Therapy Is Initiated

If treatment is warranted, target mid-normal testosterone (450–600 ng/dL) and monitor closely for adverse effects. 1, 2

• At 2–3 months: measure testosterone (midway between injections for injectables), hematocrit, and PSA. 1
• Withhold therapy immediately if hematocrit exceeds 54%; consider therapeutic phlebotomy in high-risk patients. 1
• Every 3–6 months during the first year: repeat testosterone, hematocrit, PSA, lipid profile, and digital rectal examination. 1
• Discontinue therapy at 12 months if there is no improvement in sexual function, as continued exposure without benefit is unjustified. 1

Common Pitfalls to Avoid

• Do not target supraphysiologic testosterone levels (>700 ng/dL) as this increases adverse event risk without additional clinical benefit. 1, 2
• Do not measure testosterone at peak (days 2–5 post-injection) as supraphysiologic peaks do not reflect average exposure and may lead to inappropriate dose escalation. 1
• Do not continue therapy without documented symptomatic improvement, particularly in sexual function domains where benefit is most reliably demonstrated. 1
• Do not ignore cardiovascular risk factors in a 60-year-old man; target mid-range levels (350–600 ng/dL) in elderly patients or those with chronic illness. 1

In summary, there is no legitimate clinical rationale for targeting testosterone levels of 850 ng/dL in a 60-year-old man. Guideline-recommended targets of 450–600 ng/dL balance efficacy with safety and are supported by the highest-quality evidence. 1, 2, 4